Kristina Burow is a Managing Director with ARCH Venture Partners. She is focused on the creation and development of biotechnology, pharmaceutical, and agbiotechnology companies. Since joining ARCH in 2002 Kristina has played a significant role in the creation and development of a number of companies. She is a Director of Vividion Therapeutics, Gossamer Bio (GOSS), Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals (SNNA), Metacrine, Scholar Rock (SRRK), Unity Biotechnology (UBX), Beam Therapeutics, Llama Therapeutics, AgBiome, AgTech Accelerator, and Vir Biotechnology. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene) and has participated in a number of other ARCH portfolio companies including Siluria Technologies, Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Ikaria (acquired by Mallinckrodt) and was a co-founder and board member of Sapphire Energy.
Prior to joining ARCH, Kristina was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed chemistry operations and was active in business development where she helped create numerous companies as spin-outs from GNF. She holds an MBA from the University of Chicago, an M.A. in Chemistry from Columbia University, and a B.S. in Chemistry from the University of California, Berkeley